Iron Deficiency in Heart Failure and Pulmonary Hypertension.
Pieter MartensWai Hong Wilson TangPublished in: Current treatment options in cardiovascular medicine (2022)
Iron deficiency is common co-morbidity in heart failure and pulmonary hypertension. The high prevalence is intertwined into the pathophysiology of these conditions (e.g., neurohormonal activation, inflammation). The presence of iron deficiency has a negative impact on cardiomyocytes and cardiac function, skeletal muscle function, and pulmonary vascular function. In heart failure data from over 2000 randomized patients with iron deficiency using a uniform diagnosis, have illustrated beneficial effects on functional status, quality of life, reverse cardiac remodeling, and heart failure admissions. While iron deficiency is recognized to be prevalent in pulmonary hypertension and associated with worse functional status, the absence of a uniform definition and the absence of large prospective randomized controlled trials with iron therapies limits the conclusions on the causal role of iron deficiency such as observed in heart failure.
Keyphrases
- iron deficiency
- heart failure
- pulmonary hypertension
- left ventricular
- pulmonary artery
- skeletal muscle
- cardiac resynchronization therapy
- pulmonary arterial hypertension
- atrial fibrillation
- randomized controlled trial
- oxidative stress
- insulin resistance
- risk factors
- systematic review
- double blind
- coronary artery
- machine learning
- endothelial cells